Biotech · Private company · Tigard, OR, US

Virogenomics Biodevelopment, Inc.

Track this companyFree. Adds Virogenomics Biodevelopment, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signalingFiscal year 2026 · $399.9KNIH RePORTER 1R41DA064189-01 · fetched Nov 12, 2026
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorderFiscal year 2026 · $3.3MNIH RePORTER 5UG3DA061709-02 · fetched Nov 12, 2026
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorderFiscal year 2025 · $3.3MNIH RePORTER 1UG3DA061709-01 · fetched Nov 12, 2026
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use DisorderFiscal year 2024 · $405.3KNIH RePORTER 1R41DA059296-01A1 · fetched Nov 12, 2026